|
SE0202463D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
RS52010B
(en)
*
|
2005-06-22 |
2012-04-30 |
Plexxikon Inc. |
DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
|
|
US20130210034A1
(en)
|
2005-11-04 |
2013-08-15 |
Beckman Coulter, Inc. |
Complex phosphoprotein activation profiles
|
|
US20070105165A1
(en)
|
2005-11-04 |
2007-05-10 |
Charles Goolsby |
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
|
|
US7812143B2
(en)
|
2006-03-31 |
2010-10-12 |
Memorial Sloan-Kettering Cancer Center |
Biomarkers for cancer treatment
|
|
MX2009002936A
(es)
|
2006-09-19 |
2009-04-01 |
Novartis Ag |
Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
|
|
WO2008120004A1
(en)
|
2007-04-02 |
2008-10-09 |
Astrazeneca Ab |
Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
|
|
EP1977765A1
(en)
|
2007-04-03 |
2008-10-08 |
Diatos |
Peptide prodrugs
|
|
WO2008148522A2
(en)
|
2007-06-04 |
2008-12-11 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Method to identify modulators of b-raf protein kinase and their use for the treatment of anxiety and depression
|
|
CA2639416C
(en)
|
2007-09-11 |
2019-12-31 |
F. Hoffmann-La Roche Ag |
Diagnostic test for susceptibility to b-raf kinase inhibitors
|
|
CN104601504B
(zh)
|
2008-07-01 |
2018-12-04 |
爱立信电话股份有限公司 |
在mimo电信***中使用预编码矩阵的方法和设备
|
|
JP2011527703A
(ja)
|
2008-07-11 |
2011-11-04 |
ノバルティス アーゲー |
（ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
|
|
US20110293750A1
(en)
|
2008-11-11 |
2011-12-01 |
Yale University |
Activated wnt-beta-catenin signaling in melanoma
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
EP2406259A1
(en)
|
2009-03-11 |
2012-01-18 |
Plexxikon, Inc. |
Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases
|
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
|
NZ594398A
(en)
|
2009-04-03 |
2014-03-28 |
Plexxikon Inc |
Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
|
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
US20120164148A1
(en)
|
2009-08-07 |
2012-06-28 |
The Wistar Institute |
Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
|
|
WO2011022335A1
(en)
|
2009-08-21 |
2011-02-24 |
Mount Sinai School Of Medicine Of New York University |
Methods of using cd44 fusion proteins to treat cancer
|
|
WO2011060216A1
(en)
|
2009-11-12 |
2011-05-19 |
Concert Pharmaceuticals Inc. |
Substituted azaindoles
|
|
CN102753549A
(zh)
*
|
2009-12-23 |
2012-10-24 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
US9260417B2
(en)
|
2010-02-08 |
2016-02-16 |
Amitech Therapeutic Solutions, Inc. |
Therapeutic methods and compositions involving allosteric kinase inhibition
|
|
WO2011112678A1
(en)
|
2010-03-09 |
2011-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
|
|
KR101844088B1
(ko)
|
2010-03-24 |
2018-03-30 |
아미텍 테러퓨틱 솔루션즈 인크 |
인산화효소 억제에 유용한 헤테로환 화합물
|
|
WO2011156588A1
(en)
|
2010-06-09 |
2011-12-15 |
Dana-Farber Cancer Institute, Inc. |
A mek 1 mutation conferring resistance to raf and mek inhibitors
|
|
US9125899B1
(en)
|
2010-06-17 |
2015-09-08 |
Stc.Unm |
Modulators of GTPases and their use
|
|
US8779150B2
(en)
|
2010-07-21 |
2014-07-15 |
Hoffmann-La Roche Inc. |
Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
|
|
EP2598657B1
(en)
|
2010-08-01 |
2016-10-05 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Microrna patterns for the diagnosis, prognosis and treatment of melanoma
|
|
WO2012021778A2
(en)
|
2010-08-12 |
2012-02-16 |
The Regents Of The University Of California |
Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
|
|
US8709419B2
(en)
|
2010-08-17 |
2014-04-29 |
Hoffmann-La Roche, Inc. |
Combination therapy
|
|
US20120045433A1
(en)
|
2010-08-17 |
2012-02-23 |
Kapil Dhingra |
Combination therapy
|
|
WO2012027536A1
(en)
|
2010-08-26 |
2012-03-01 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
|
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
|
WO2012030738A2
(en)
|
2010-08-30 |
2012-03-08 |
Beckman Coulter, Inc. |
Complex phosphoprotein activation profiles
|
|
US9089570B2
(en)
|
2010-09-03 |
2015-07-28 |
Tactical Therapeutics Inc |
Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
EP2616467A1
(en)
|
2010-09-13 |
2013-07-24 |
Concert Pharmaceuticals Inc. |
Substituted azaindoles
|
|
US20120064135A1
(en)
|
2010-09-15 |
2012-03-15 |
Norac Pharma |
Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
|
|
AU2011310096B2
(en)
|
2010-09-30 |
2014-11-06 |
Deutsches Krebsforschungszentrum |
Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
|
|
US20120095078A1
(en)
|
2010-10-07 |
2012-04-19 |
Sanford-Burnham Medical Research Institute |
Methods of diagnosis and treatment of melanoma
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
US20120108457A1
(en)
|
2010-10-11 |
2012-05-03 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
US20120276122A1
(en)
|
2010-11-01 |
2012-11-01 |
Sanford-Burnham Medical Research Institute |
Methods for diagnosis and treatment of cellular proliferative disorders
|
|
EA201390740A1
(ru)
|
2010-11-19 |
2013-12-30 |
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед |
Способ лечения с использованием ингибитора braf
|
|
WO2012068562A2
(en)
|
2010-11-19 |
2012-05-24 |
The Regents Of The University Of California |
Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
|
|
US9289456B2
(en)
|
2010-11-22 |
2016-03-22 |
Nova Southeastern University |
Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment
|
|
WO2012075324A1
(en)
|
2010-12-02 |
2012-06-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods for treating a tumor using an antibody that specifically binds hmw-maa
|
|
US9295669B2
(en)
|
2010-12-14 |
2016-03-29 |
Hoffman La-Roche Inc. |
Combination therapy for proliferative disorders
|
|
US20130004481A1
(en)
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
ES2696023T3
(es)
*
|
2011-02-07 |
2019-01-11 |
Plexxikon Inc |
Compuestos y métodos para la modulación de quinasas e indicaciones para ello
|
|
WO2012109329A2
(en)
|
2011-02-08 |
2012-08-16 |
Children's Medical Center Corporation |
Methods for treatment of melanoma
|
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
|
MX352844B
(es)
|
2011-02-28 |
2017-12-11 |
Calitor Sciences Llc |
Compuestos de quinolina sustituidos y metodos de uso.
|
|
WO2012117396A1
(en)
|
2011-03-01 |
2012-09-07 |
Novotyr Therapeutics Ltd |
Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
|
|
WO2012119095A1
(en)
|
2011-03-02 |
2012-09-07 |
Board Of Regents, The University Of Texas System |
Fus1/tusc2 therapies
|
|
CA2828940C
(en)
|
2011-03-10 |
2024-04-16 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
|
KR20140025434A
(ko)
|
2011-04-01 |
2014-03-04 |
제넨테크, 인크. |
Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
|
|
EP2694677A2
(en)
|
2011-04-04 |
2014-02-12 |
Netherland Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
|
US8680066B2
(en)
|
2011-04-05 |
2014-03-25 |
The United States of America as represented by the Development of Veterans Affairs |
Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject
|
|
WO2012138809A1
(en)
|
2011-04-05 |
2012-10-11 |
Dawei Zhang |
Heterocyclic compounds as kinase inhibitors
|
|
EP2508607A1
(en)
|
2011-04-07 |
2012-10-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for liver regeneration and for treatment of liver failure
|
|
MX2013011518A
(es)
|
2011-04-08 |
2014-06-04 |
Afraxis Holdings Inc |
8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
|
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
GB201107176D0
(en)
|
2011-04-28 |
2011-06-15 |
Cxr Biosciences Ltd |
Pyrrolnitrin derivatives
|
|
GB201107197D0
(en)
|
2011-04-28 |
2011-06-15 |
Cxr Biosciences Ltd |
Compounds
|
|
WO2012149547A1
(en)
|
2011-04-28 |
2012-11-01 |
Duke University |
Methods of treating hemoglobinopathies
|
|
US20140050696A1
(en)
|
2011-04-29 |
2014-02-20 |
Ravi K. Amaravadi |
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
|
|
US9746470B2
(en)
|
2011-05-09 |
2017-08-29 |
Whitehead Institute For Biomedical Research |
Chaperone interaction assays and uses thereof
|
|
US9221760B2
(en)
|
2011-05-09 |
2015-12-29 |
Van Andel Research Institute |
Autophagy inhibitors
|
|
AU2012253525B2
(en)
|
2011-05-10 |
2016-09-22 |
Brunangelo Falini |
Hairy cell leukemia biomarkers and methods of using same
|
|
US20140127316A1
(en)
|
2011-05-20 |
2014-05-08 |
New York University |
Propolis and caffeic acid phenethyl ester and uses thereof
|
|
US9481910B2
(en)
|
2011-05-25 |
2016-11-01 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for the detection of drug resistant BRAF isoforms
|
|
US9375484B2
(en)
|
2011-05-31 |
2016-06-28 |
Regents Of The University Of Minnesota |
Taxane silicate prodrugs and nanoparticles
|
|
PT3446714T
(pt)
|
2011-06-02 |
2021-06-23 |
Univ Louisville Res Found Inc |
Nanopartículas conjugadas a um agente antinucleolina
|
|
EP3326616B1
(en)
|
2011-06-03 |
2021-07-28 |
Signpath Pharma Inc. |
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
|
|
CA2838387A1
(en)
|
2011-06-06 |
2012-12-13 |
Chevron Phillips Chemical Company Lp |
Use of metallocene compounds for cancer treatment
|
|
US20140222443A1
(en)
|
2011-06-07 |
2014-08-07 |
Kathleen Danenberg |
Molecular profiling for cancer
|
|
US20120321637A1
(en)
|
2011-06-20 |
2012-12-20 |
The Board Of Regents Of The University Of Texas System |
Combination cancer therapy with herv inhibition
|
|
WO2012178038A1
(en)
|
2011-06-24 |
2012-12-27 |
The Broad Institute, Inc. |
Methods of treating cancer
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
WO2013044169A1
(en)
|
2011-09-21 |
2013-03-28 |
Nestec S.A. |
Methods for determining combination therapy with il-2 for the treatment of cancer
|
|
WO2013052608A1
(en)
|
2011-10-07 |
2013-04-11 |
Sanford-Burnham Medical Research Institute |
Optically pure apogossypolone derivatives as pan-active inhibitors of anti-apoptotic bcl-2 family proteins
|
|
BR112014009953A2
(pt)
|
2011-10-28 |
2017-12-05 |
Genentech Inc |
método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
|
|
WO2013074594A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
GB201121869D0
(en)
|
2011-11-17 |
2012-02-01 |
Clarient Inc |
Method of allele-specific amplification
|
|
CN106075450A
(zh)
|
2011-11-22 |
2016-11-09 |
塔夫茨大学信托人 |
用于树突状细胞癌症疫苗的小分子增强剂
|
|
CN104080461A
(zh)
|
2011-11-30 |
2014-10-01 |
雪松-西奈医学中心 |
靶向微小rna mir-409-5p、mir-379和mir-154*来治疗***癌骨转移和耐药性肺癌
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
WO2013086260A2
(en)
|
2011-12-09 |
2013-06-13 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of cancer
|
|
US20130172375A1
(en)
|
2011-12-13 |
2013-07-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical composition
|
|
PL2802314T3
(pl)
|
2012-01-13 |
2021-06-14 |
Xspray Microparticles Ab |
Sposób wytwarzania stabilnych, amorficznych hybrydowych nanocząstek zawierających co najmniej jeden inhibitor kinazy białkowej i co najmniej jeden polimerowy składnik stabilizujący i tworzący macierz
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
US9624235B2
(en)
|
2012-01-31 |
2017-04-18 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity
|
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
|
US9663826B2
(en)
|
2012-02-15 |
2017-05-30 |
The Translational Genomics Research Institute |
System and method of genomic profiling
|
|
EP2817004B1
(en)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
|
US9880171B2
(en)
|
2012-03-02 |
2018-01-30 |
Ludwig Institute For Cancer Research Ltd. |
iASPP phosphorylation and metastatic potential
|
|
WO2013134467A1
(en)
|
2012-03-07 |
2013-09-12 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Selective histone deactylase 6 inhibitors
|
|
EP2823307A4
(en)
|
2012-03-08 |
2015-07-29 |
Bioscale Inc |
METHOD AND KITS FOR ANALYZING BIOMARKERS IN A SIGNAL TRANSDUCTION PATH
|
|
WO2013138371A1
(en)
|
2012-03-12 |
2013-09-19 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
|
|
WO2013138210A1
(en)
|
2012-03-14 |
2013-09-19 |
Ning Xi |
Substituted cyclic compounds and methods of use
|
|
US9725427B2
(en)
|
2012-03-16 |
2017-08-08 |
Biohaven Pharmaceutical Holding Company Limited |
Prodrugs of riluzole and their method of use
|
|
US9358235B2
(en)
|
2012-03-19 |
2016-06-07 |
Plexxikon Inc. |
Kinase modulation, and indications therefor
|
|
US9216170B2
(en)
|
2012-03-19 |
2015-12-22 |
Hoffmann-La Roche Inc. |
Combination therapy for proliferative disorders
|
|
KR101497972B1
(ko)
|
2012-03-21 |
2015-03-03 |
서울대학교산학협력단 |
Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제
|
|
US9464326B2
(en)
|
2012-03-22 |
2016-10-11 |
University Of Maryland, Baltimore |
Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
|
|
PL2831589T3
(pl)
|
2012-03-28 |
2018-10-31 |
Dana-Farber Cancer Institute, Inc. |
Mutanty C-RAF, które nadają oporność na inhibitory RAF
|
|
WO2013148537A1
(en)
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
KR20150002706A
(ko)
|
2012-03-29 |
2015-01-07 |
알토 바이오사이언스 코포레이션 |
종양 형성 치료방법
|
|
US20130288980A1
(en)
|
2012-04-02 |
2013-10-31 |
Buck Institute For Research On Aging |
Targeting senescent and cancer cells for selective killing by interference with foxo4
|
|
CN104684579A
(zh)
|
2012-04-02 |
2015-06-03 |
梅里麦克制药股份有限公司 |
单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
|
|
US20130288981A1
(en)
|
2012-04-02 |
2013-10-31 |
Buck Institute For Research On Aging |
Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
|
|
WO2013155077A1
(en)
|
2012-04-09 |
2013-10-17 |
Board Of Regents,The University Of Texas System |
Response markers for src inhibitor therapies
|
|
WO2013165320A1
(en)
|
2012-05-04 |
2013-11-07 |
Agency For Science, Technology And Research |
Treating cancer by increasing expression of socs6
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
AU2013259387B2
(en)
|
2012-05-09 |
2016-12-15 |
Strike Bio, Inc. |
Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
|
|
CA2871540A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
|
WO2013173500A2
(en)
|
2012-05-15 |
2013-11-21 |
New York University |
Method for predicting recurrence of melanoma using mirna alterations
|
|
AU2013262655A1
(en)
|
2012-05-16 |
2014-12-04 |
John Wayne Cancer Institute |
Immunological markers for adjuvant therapy in melanoma
|
|
WO2013171753A1
(en)
|
2012-05-16 |
2013-11-21 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
|
|
WO2013177092A1
(en)
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
|
WO2013180949A1
(en)
|
2012-05-27 |
2013-12-05 |
Ning Xi |
Substituted quinoline compounds and methods of use
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
US20130330761A1
(en)
|
2012-06-12 |
2013-12-12 |
Celcuity, LLC |
Whole cell assays and methods
|
|
US20130336889A1
(en)
|
2012-06-14 |
2013-12-19 |
National Taiwan University |
Nanoparticle and method for detecting or treating a tumor using the same
|
|
US9220695B2
(en)
|
2012-06-29 |
2015-12-29 |
The Research Foundation For The State University Of New York |
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
|
|
US10478446B2
(en)
|
2012-07-03 |
2019-11-19 |
Fondazione Centro San Raffaele Office Of Biotechnology Transfer |
Compounds for use in polycystic kidney disease
|
|
EA201590041A1
(ru)
|
2012-07-03 |
2015-04-30 |
Ратиофарм Гмбх |
Твердая форма холиновой соли вемурафениба
|
|
WO2014009319A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
WO2014009318A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
GB201212586D0
(en)
|
2012-07-16 |
2012-08-29 |
Univ Murcia |
Cancer treatment
|
|
WO2014018862A1
(en)
|
2012-07-27 |
2014-01-30 |
Corning Incorporated |
Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer
|
|
EP2877159B8
(en)
|
2012-07-27 |
2018-02-14 |
Izumi Technology, LLC. |
Efflux inhibitor compositions and methods of treatment using the same
|
|
EP2879676B1
(en)
|
2012-07-28 |
2017-06-14 |
Calitor Sciences, LLC |
Substituted pyrazolone compounds and methods of use
|
|
WO2014022128A1
(en)
|
2012-07-29 |
2014-02-06 |
Calitor Sciences, Llc |
Pi3 kinase modulators and methods of use
|
|
AU2013296233B2
(en)
|
2012-08-03 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
|
WO2014028461A2
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
US20140045883A1
(en)
|
2012-08-13 |
2014-02-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Ack1 kinase inhibition to treat triple negative breast cancer
|
|
SG10201913359TA
(en)
|
2012-08-17 |
2020-02-27 |
Hoffmann La Roche |
Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
|
|
WO2014031856A1
(en)
|
2012-08-23 |
2014-02-27 |
Onconthyreon Inc. |
Combination therapy using pi3 kinase and braf inhibitors
|
|
TWI601725B
(zh)
|
2012-08-27 |
2017-10-11 |
加拓科學公司 |
取代的氮雜吲哚化合物及其鹽、組合物和用途
|
|
EP2897631A4
(en)
|
2012-08-31 |
2016-10-05 |
Univ Virginia Patent Found |
TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS
|
|
US9561245B2
(en)
|
2012-09-06 |
2017-02-07 |
The Board Of Regents Of The University Of Texas System |
Combination treatments for melanoma
|
|
AU2013317985B2
(en)
|
2012-09-19 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Dynamic BH3 profiling
|
|
CA2886397A1
(en)
|
2012-09-26 |
2014-04-03 |
Insight Genetics, Inc. |
Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
|
|
CN103172744B
(zh)
|
2012-09-28 |
2016-01-13 |
武汉纽斯特生物技术有限公司 |
特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
|
|
CA2887058C
(en)
|
2012-10-03 |
2022-02-22 |
Exosome Diagnostics, Inc. |
Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
|
|
SI2903616T1
(en)
|
2012-10-04 |
2018-02-28 |
Ab Science |
The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
|
|
EA028605B1
(ru)
|
2012-10-08 |
2017-12-29 |
Атрива Терапьютикс Гмбх |
Комбинация озельтамивира и ингибитора mek для лечения вирусных заболеваний
|
|
WO2014058317A1
(en)
|
2012-10-10 |
2014-04-17 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Methods and means for predicting resistance to anti-cancer treatment
|
|
EP2908830A4
(en)
|
2012-10-18 |
2016-11-30 |
Univ Western Australia |
CANCER THERAPY WITH MIRNAS
|
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
|
US20150283136A1
(en)
|
2012-11-08 |
2015-10-08 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
US20140147411A1
(en)
|
2012-11-14 |
2014-05-29 |
U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS |
Methods of treating cancer and testing mutation zygosity related thereto
|
|
TWI574962B
(zh)
|
2012-11-14 |
2017-03-21 |
加拓科學公司 |
作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
EP2922572A1
(en)
|
2012-11-23 |
2015-09-30 |
AB Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
WO2014089280A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Alkynyl compounds and methods of use
|
|
US9945863B2
(en)
|
2012-12-14 |
2018-04-17 |
The Research Foundation Of State University Of New York |
Coiled coil helix cristae morphology 1 (CHCM1) tumor marker and cancer therapeutic target
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
EP2935569B1
(en)
|
2012-12-21 |
2019-05-01 |
Celverum Inc. |
Non-replicating rhabdovirus-derived particles and uses thereof
|
|
EP4129286A1
(en)
|
2012-12-27 |
2023-02-08 |
Quest Diagnostics Investments Incorporated |
Ddr2 mutations as targetable features of melanoma or basal cell carcinoma
|
|
WO2014107718A2
(en)
|
2013-01-07 |
2014-07-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
|
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
|
CA2898329A1
(en)
|
2013-01-19 |
2014-07-24 |
New York University |
Oligooxopiperazines for p53 reactivation
|
|
US9605026B2
(en)
|
2013-01-19 |
2017-03-28 |
New York University |
Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
|
|
SG11201505493QA
(en)
|
2013-02-21 |
2015-08-28 |
Calitor Sciences Llc |
Heteroaromatic compounds as pi3 kinase modulators
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
US20140243211A1
(en)
|
2013-02-28 |
2014-08-28 |
Indiana University Research & Technology Corporation |
Blood biomarkers for suicidality
|
|
MX2015011713A
(es)
|
2013-03-05 |
2016-05-09 |
Univ Tennessee Res Foundation |
Compuestos para el tratamiento de cancer.
|
|
US9937161B2
(en)
|
2013-03-06 |
2018-04-10 |
The General Hospital Corporation |
Combinatorial compositions and methods for treatment of melanoma
|
|
WO2015073072A1
(en)
|
2013-11-15 |
2015-05-21 |
Oncoceutics, Inc. |
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
|
|
KR20150130491A
(ko)
|
2013-03-13 |
2015-11-23 |
제넨테크, 인크. |
피라졸로 화합물 및 그것의 용도
|
|
NZ711948A
(en)
|
2013-03-13 |
2020-02-28 |
Oncoceutics Inc |
Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
|
|
CN110420329A
(zh)
|
2013-03-14 |
2019-11-08 |
佛罗里达大学研究基金会 |
利用天然化合物和/或饮食调控癌症
|
|
CN105008356A
(zh)
|
2013-03-14 |
2015-10-28 |
拉蒂奥法姆有限责任公司 |
固态形式的盐酸威罗菲尼
|
|
WO2014160358A1
(en)
|
2013-03-14 |
2014-10-02 |
Thomas Cooper Woods |
Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
US20150079584A1
(en)
|
2013-03-15 |
2015-03-19 |
Kiyatec Inc. |
Bioreactor system
|
|
US9920377B2
(en)
|
2013-03-15 |
2018-03-20 |
Sutter West Bay Hospitals |
FALZ for use as a target for therapies to treat cancer
|
|
WO2014151304A1
(en)
|
2013-03-15 |
2014-09-25 |
Golden Biotechnology Corporation |
Therapeutic methods and compositions utilizing cyclohexenone compounds
|
|
JP2016515380A
(ja)
|
2013-03-15 |
2016-05-30 |
ライフ テクノロジーズ コーポレーション |
肺癌の分類及び実施可能性インデックス
|
|
RU2015138995A
(ru)
|
2013-03-15 |
2017-04-19 |
Санофи |
Противоопухолевая композиция, содержащая ингибитор pi3k-бета и ингибитор raf, для преодоления резистентности раковых клеток
|
|
JP2016519091A
(ja)
|
2013-03-18 |
2016-06-30 |
ジェノシアンス ファルマ |
新規抗がん剤としてのキノリン誘導体
|
|
US20160058751A1
(en)
|
2013-03-28 |
2016-03-03 |
Cellworks Group, Inc. |
Composition and method for treating cancer
|
|
WO2014165644A2
(en)
|
2013-04-04 |
2014-10-09 |
The General Hospital Corporation |
Combination treatments with sonic hedgehog inhibitors
|
|
CN105263496A
(zh)
|
2013-04-08 |
2016-01-20 |
药品循环有限责任公司 |
依鲁替尼联合疗法
|
|
WO2014168721A2
(en)
|
2013-04-12 |
2014-10-16 |
Tufts Medical Center |
Methods and systems for designing and/or characterizing soluble lipidated ligand agents
|
|
AU2014253040A1
(en)
|
2013-04-13 |
2015-11-05 |
Universidade De Coimbra |
Platform for targeted delivery to stem cells and tumor cells and uses thereof
|
|
CN105378110A
(zh)
|
2013-04-17 |
2016-03-02 |
生命技术公司 |
与癌症相关的基因融合体和基因变异体
|
|
WO2014177038A1
(en)
|
2013-04-28 |
2014-11-06 |
Sunshine Lake Pharma Co., Ltd. |
Aminoquinazoline derivatives and their salts and methods of use thereof
|
|
WO2014177915A1
(en)
|
2013-05-01 |
2014-11-06 |
Piramal Enterprises Limited |
Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
|
|
US20140335077A1
(en)
|
2013-05-07 |
2014-11-13 |
Leonard Girnita |
Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors
|
|
US20160101106A1
(en)
|
2013-05-07 |
2016-04-14 |
Inhibikase Therapeutics, Inc. |
Methods for treating hcv infection
|
|
AU2014267337B2
(en)
|
2013-05-13 |
2020-04-02 |
Institut Gustave Roussy |
Prognosis and predictive biomarkers and biological applications thereof
|
|
WO2014193647A2
(en)
|
2013-05-26 |
2014-12-04 |
Calitor Sciences, Llc |
Alkenyl compounds and methods of use
|
|
RU2015149937A
(ru)
|
2013-05-30 |
2017-07-06 |
Плексксикон Инк. |
Соединения для модулирования киназы и показания к их применению
|
|
WO2014204856A1
(en)
|
2013-06-17 |
2014-12-24 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid anticancer derivatives and their uses
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
EP3674300B1
(en)
|
2013-06-21 |
2022-10-12 |
Zenith Epigenetics Ltd. |
Novel bicyclic bromodomain inhibitors
|
|
EP3010918B1
(en)
|
2013-06-21 |
2018-08-15 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
CN117731786A
(zh)
|
2013-07-12 |
2024-03-22 |
皮拉马尔企业有限公司 |
用于治疗黑素瘤的药物组合
|
|
US9751832B2
(en)
|
2013-07-30 |
2017-09-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Selective histone deactylase 6 inhibitors
|
|
WO2015017729A1
(en)
|
2013-07-31 |
2015-02-05 |
Virginia Tech Intellectual Properties, Inc. |
Dielectrophoresis methods for determining a property of a plurality of cancer cells
|
|
US20160166637A1
(en)
|
2013-08-02 |
2016-06-16 |
Virginia Tech Intellectual Properties, Inc. |
Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
|
|
US20150056195A1
(en)
|
2013-08-23 |
2015-02-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
|
|
CN104415335A
(zh)
|
2013-09-02 |
2015-03-18 |
北京中康万达医药科技有限公司 |
体内个体化***免疫治疗方法和装置
|
|
WO2015034519A1
(en)
|
2013-09-03 |
2015-03-12 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
WO2015034729A1
(en)
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
|
CA2923829A1
(en)
|
2013-09-10 |
2015-03-19 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
|
BR112016005303A2
(pt)
|
2013-09-11 |
2017-09-12 |
Medimmune Ltd |
anticorpos anti-b7-h1 para tratamento de tumores
|
|
WO2015037005A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd. |
Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
|
|
US20160223547A1
(en)
|
2013-09-13 |
2016-08-04 |
Angels SIERRA JIMÉNLEZ |
Marker for predicting metastasis of breast cancer
|
|
WO2015039107A1
(en)
|
2013-09-16 |
2015-03-19 |
The Johns Hopkins University |
Activities of multiple cancer-related pathways are associated with braf mutation and predict the resistance to braf/mek inhibitors in melanoma cells
|
|
US9695402B2
(en)
|
2013-09-17 |
2017-07-04 |
Yeda Research And Development Co. Ltd. |
ERK-derived peptides and uses thereof
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
WO2015041533A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
US20150086509A1
(en)
|
2013-09-25 |
2015-03-26 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating cancer using interferon and mapk pathway inhibitor
|
|
CN104513259B
(zh)
|
2013-09-26 |
2017-06-16 |
广东东阳光药业有限公司 |
取代脲衍生物及其在药物中的应用
|
|
JP6527508B2
(ja)
|
2013-10-01 |
2019-06-05 |
メディミューン リミテッド |
αＶβ６を過剰発現する癌を治療及び診断する方法
|
|
US20160244845A1
(en)
|
2013-10-04 |
2016-08-25 |
Ab Science |
Method for determining the prognosis of pancreatic cancer
|
|
WO2015058056A1
(en)
|
2013-10-18 |
2015-04-23 |
The General Hospital Corporation |
N-methyl pyrazoloanthrone for treatment of cancer
|
|
US9724657B2
(en)
|
2013-10-22 |
2017-08-08 |
Tyme, Inc. |
High-speed centrifugal mixing devices and methods of use
|
|
US9585841B2
(en)
|
2013-10-22 |
2017-03-07 |
Tyme, Inc. |
Tyrosine derivatives and compositions comprising them
|
|
WO2015066439A2
(en)
|
2013-11-01 |
2015-05-07 |
Foundation Medicine, Inc. |
Methods of treating hematological malignancies
|
|
WO2015066452A2
(en)
|
2013-11-01 |
2015-05-07 |
Foundation Medicine, Inc. |
Methods of treating pediatric cancers
|
|
WO2015069266A1
(en)
|
2013-11-07 |
2015-05-14 |
Flynn Daniel L |
Methods for inhibiting tie2 kinase useful in the treatment of cancer
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
BR112016010564A2
(pt)
|
2013-11-11 |
2017-10-10 |
Amgen Inc |
terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
|
|
WO2015073644A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
|
EP3068364B1
(en)
|
2013-11-14 |
2021-11-03 |
Metro Biotech NSW Pty Ltd |
Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
|
|
US20160298198A1
(en)
|
2013-11-15 |
2016-10-13 |
New York University |
Method for predicting development of melanoma brain metastasis
|
|
KR20240006008A
(ko)
|
2013-11-15 |
2024-01-12 |
온코슈틱스 인코포레이티드 |
7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도
|
|
US9717715B2
(en)
|
2013-11-15 |
2017-08-01 |
Samsung Electronics Co., Ltd. |
Method of combination therapy using an anti-C-Met antibody
|
|
WO2015075749A1
(en)
|
2013-11-22 |
2015-05-28 |
Laurus Labs Private Limited |
Novel processes for the preparation of vemurafenib
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
CZ2013943A3
(cs)
|
2013-11-27 |
2015-06-03 |
Zentiva, K.S. |
Krystalické formy vemurafenibu
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
WO2015085229A1
(en)
|
2013-12-08 |
2015-06-11 |
Van Andel Research Institute |
Autophagy inhibitors
|
|
WO2015089380A2
(en)
|
2013-12-12 |
2015-06-18 |
Celcuity Llc |
Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
|
|
EP3178943B1
(en)
|
2013-12-17 |
2018-10-03 |
Csir |
A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds
|
|
EP3082800B1
(en)
|
2013-12-20 |
2022-02-02 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
WO2015095767A1
(en)
|
2013-12-20 |
2015-06-25 |
3-V Biosciences, Inc. |
Heterocyclic modulators of lipid synthesis and combinations thereof
|
|
WO2015095842A2
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
|
|
WO2015097621A2
(en)
|
2013-12-23 |
2015-07-02 |
Novartis Ag |
Pharmaceutical combinations
|
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合ｅｇｆｒ及ｍｅｔ之多功能抗體
|
|
US11623946B2
(en)
|
2013-12-27 |
2023-04-11 |
National University Corporation Tokyo Medical And Dental University |
Diagnosis methods, diagnostic agents, and therapeutic agents against alzheimer's disease and frontotemporal lobar degeneration, and screening methods for these agents
|
|
US20160376374A1
(en)
|
2014-01-02 |
2016-12-29 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
|
|
WO2015104292A2
(en)
|
2014-01-07 |
2015-07-16 |
Biomedical Research Foundation Of The Academy Of Athens |
Compounds for use in treating or preventing cancerous diseases
|
|
EP3092232B1
(en)
|
2014-01-07 |
2022-03-09 |
Sagimet Biosciences Inc. |
Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
|
|
EP3091970B1
(en)
|
2014-01-10 |
2020-10-28 |
Rgenix, Inc. |
Lxr agonists and uses thereof
|
|
AU2015210886A1
(en)
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
MX2016010213A
(es)
|
2014-02-07 |
2017-04-13 |
Auspex Pharmaceuticals Inc |
Formulaciones farmaceuticas novedosas.
|
|
ZA201500995B
(en)
|
2014-02-12 |
2015-12-23 |
Cipla Ltd |
Low dose pharmaceutical composition
|
|
US20150231069A1
(en)
|
2014-02-20 |
2015-08-20 |
Pankaj Modi |
Oral formulations of chemotherapeutic agents
|
|
CA2975829A1
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
|
|
WO2015130922A2
(en)
|
2014-02-26 |
2015-09-03 |
The Trustees Of The University Of Pennsylvania |
Small molecule hsp70 inhibitors
|
|
WO2015135094A1
(en)
|
2014-03-13 |
2015-09-17 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US20150269307A1
(en)
|
2014-03-18 |
2015-09-24 |
Texas Tech University System |
Target inhibition map system for combination therapy design and methods of using same
|
|
EP3131586A4
(en)
|
2014-03-18 |
2017-10-25 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics
|
|
JP2017514793A
(ja)
|
2014-03-26 |
2017-06-08 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
|
|
ES2926934T3
(es)
|
2014-03-28 |
2022-10-31 |
Univ Degli Studi Genova |
Inhibidores de tirosina quinasa para uso en un método de tratar cáncer en asociación con una ingesta calórica reducida
|
|
WO2015153657A2
(en)
|
2014-04-01 |
2015-10-08 |
Texas Tech University System |
Overcoming chemotherapeutic agent resistance in cancer by inhibiting mcl-1
|
|
EP3125940A2
(en)
|
2014-04-01 |
2017-02-08 |
Université Libre de Bruxelles |
New strategies for treating melanoma
|
|
US20170202847A1
(en)
|
2014-04-04 |
2017-07-20 |
The University Of North Carolina At Chapel Hill |
Methods for the treatment of tumors
|
|
US10016421B2
(en)
|
2014-04-05 |
2018-07-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
|
|
EP3129367B1
(en)
|
2014-04-08 |
2019-09-04 |
Rigel Pharmaceuticals, Inc. |
2,3-disubstituted pyridine compounds as tgf-beta inhibitors
|
|
CN106459063A
(zh)
|
2014-04-11 |
2017-02-22 |
北卡罗来纳-查佩尔山大学 |
Mertk‑特异性嘧啶化合物
|
|
US10028958B2
(en)
|
2014-04-19 |
2018-07-24 |
Massachusetts Institute Of Technology |
Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
|
|
WO2015164161A1
(en)
|
2014-04-22 |
2015-10-29 |
Calitor Sciences, Llc |
Bicylcic pyrazolone compounds and methods of use
|
|
US20170049790A1
(en)
|
2014-05-02 |
2017-02-23 |
The Wistar Institute Of Anatomy And Biology |
Combination therapies targeting mitochondria for cancer therapy
|
|
US20170100345A1
(en)
|
2014-05-06 |
2017-04-13 |
The Regents Of The University Of California |
Wound healing using braf inhibitors
|
|
PL3142751T3
(pl)
|
2014-05-13 |
2019-12-31 |
Medimmune Limited |
Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
|
|
WO2015175965A1
(en)
|
2014-05-15 |
2015-11-19 |
The Research Foundation For Suny |
Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
|
|
CN116942832A
(zh)
|
2014-05-16 |
2023-10-27 |
归属疗法有限公司 |
抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
US20170112865A1
(en)
|
2014-05-21 |
2017-04-27 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
WO2015179855A1
(en)
|
2014-05-23 |
2015-11-26 |
Duke University |
Methods of limiting morbidity in hemoglobinopathies
|
|
US20150344957A1
(en)
|
2014-06-01 |
2015-12-03 |
Trovagene, Inc. |
Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
|
|
WO2015187496A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Hospital Medical Center |
Therapy for solid tumors
|
|
US20150342943A1
(en)
|
2014-06-03 |
2015-12-03 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
|
EP3207931A3
(en)
|
2014-06-03 |
2017-12-20 |
Signpath Pharma Inc. |
Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
|
|
US10238631B2
(en)
|
2014-06-07 |
2019-03-26 |
Academia Sinica |
Sesquiterpene derivatives and their use in inflammation or cancer treatment
|
|
US10758526B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
WO2015191996A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
WO2015193702A1
(en)
|
2014-06-17 |
2015-12-23 |
Bionsil S.R.L. In Liquidazione |
Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule
|
|
CA2952474A1
(en)
|
2014-06-23 |
2015-12-30 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
|
US9994577B2
(en)
|
2014-07-04 |
2018-06-12 |
Merck Patent Gmbh |
Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
|
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
JP6701162B2
(ja)
|
2014-07-11 |
2020-05-27 |
ゲンマブ エー／エス |
Ａｘｌに結合する抗体
|
|
US20190194757A1
(en)
|
2014-07-14 |
2019-06-27 |
Universitat Zurich Prorektorat Mnw |
Means and methods for identifying a patient having a BRAF-positive cancer as a non-responder to a BRAF inhibitor as a responder to an MAPK/ERK inhibitor
|
|
EP3169361B1
(en)
|
2014-07-15 |
2019-06-19 |
F.Hoffmann-La Roche Ag |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
EP3628308A1
(en)
|
2014-07-17 |
2020-04-01 |
BioCurity Pharmaceuticals Inc. |
Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
|
|
JP6665154B2
(ja)
|
2014-07-17 |
2020-03-13 |
ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド |
置換尿素誘導体及びその薬学的使用
|
|
US20180064765A1
(en)
|
2014-07-18 |
2018-03-08 |
Advaxis, Inc. |
Listeria-based immunogenic compositions for eliciting anti-tumor responses
|
|
CN106715719B
(zh)
|
2014-07-21 |
2022-08-02 |
福尔生物治疗有限公司 |
用于确定患者特定突变的药物反应的方法
|
|
CN105294655B
(zh)
|
2014-07-26 |
2019-03-15 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
US9828373B2
(en)
|
2014-07-26 |
2017-11-28 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
US10221140B2
(en)
|
2014-08-08 |
2019-03-05 |
The Trustees Of The University Of Pennsylvania |
Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
|
|
EP3181136B1
(en)
|
2014-08-11 |
2019-11-27 |
The University of Tokyo |
Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
|
|
WO2016025648A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a raf inhibitor and related methods
|
|
WO2016025651A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a tor inhibitor and related methods
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
EP3189049B1
(en)
|
2014-09-05 |
2024-03-20 |
Genentech, Inc. |
Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
|
|
EP3191128A4
(en)
|
2014-09-11 |
2018-03-14 |
Celldex Therapeutics, Inc. |
Uses of anti-her3 antibodies for treating cancer
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
LT3204413T
(lt)
|
2014-10-06 |
2020-01-10 |
Mayo Foundation For Medical Education And Research |
Nešiklio ir antikūno kompozicija, ir jos gamybos bei naudojimo būdai
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
WO2016055028A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
WO2016061231A1
(en)
|
2014-10-14 |
2016-04-21 |
Deciphera Pharmaceuticals, Llc |
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
|
US20170224670A1
(en)
|
2014-10-14 |
2017-08-10 |
Exelixis, Inc. |
Drug Combination to Treat Melanoma
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
WO2016066634A2
(en)
|
2014-10-27 |
2016-05-06 |
Ruprecht-Karls-Universität Heidelberg |
Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
|
|
EP3212176B1
(en)
|
2014-10-27 |
2020-11-04 |
Centre National De La Recherche Scientifique |
Panicein compounds, compositions and their use in the treatment of cancer
|
|
WO2016069928A1
(en)
|
2014-10-31 |
2016-05-06 |
Beth Israel Deaconess Medical Center |
Methods of detecting braf in cancer
|
|
US20170333404A1
(en)
|
2014-11-03 |
2017-11-23 |
Dispersol Technologies, Llc |
Improved formulations of vemurafenib and methods of making the same
|
|
US20190209576A1
(en)
|
2014-11-07 |
2019-07-11 |
AI Therapeutics, Inc. |
Apilimod for use in the treatment of colorectal cancer
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック， インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016075333A1
(en)
|
2014-11-14 |
2016-05-19 |
Vib Vzw |
Direct and selective inhibition of mdm4 for treatment of cancer
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
US10696693B2
(en)
|
2014-11-21 |
2020-06-30 |
Rigel Pharmaceuticals, Inc. |
Fused imidazole derivatives as TGF-beta inhibitors
|
|
RU2572569C1
(ru)
|
2014-11-27 |
2016-01-20 |
Федеральное государственное бюджетное научное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" (ФГБНУ "РОНЦ им. Н.Н. Блохина") |
СПОСОБ ПОЛУЧЕНИЯ ПОДКОЖНЫХ КСЕНОГРАФТОВ КЛЕТОЧНОЙ ЛИНИИ МЕЛАНОМЫ КОЖИ ЧЕЛОВЕКА mel Cher С МУТАЦИЕЙ V600E BRAF ДЛЯ ДОКЛИНИЧЕСКОГО ИЗУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ТАРГЕТНЫХ СРЕДСТВ
|
|
CN107531690B
(zh)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
|
|
US10414764B2
(en)
|
2014-11-29 |
2019-09-17 |
Shilpa Medicare Limited |
Substantially pure vemurafenib and its salts
|
|
EP3227280B1
(en)
|
2014-12-01 |
2019-04-24 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016089208A2
(en)
|
2014-12-04 |
2016-06-09 |
Stichting Maastricht Radiation Oncology "Maastro-Clinic" |
Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
US9862698B2
(en)
|
2014-12-16 |
2018-01-09 |
Adt Pharmaceuticals, Inc. |
Indenyl compounds, pharmaceutical compositions, and medical uses thereof
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
WO2016100619A2
(en)
|
2014-12-17 |
2016-06-23 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
|
US20190055235A1
(en)
|
2014-12-17 |
2019-02-21 |
Zenith Epigenetics Ltd. |
Substituted bicyclic compounds as bromodomain inhibitors
|
|
WO2016097036A1
(en)
|
2014-12-17 |
2016-06-23 |
Karo Bio Ab |
Estrogen receptor ligand for use in treating melanoma
|
|
MA41218A
(fr)
|
2014-12-19 |
2017-10-24 |
Advaxis Inc |
Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
|
|
DE102014226903A1
(de)
|
2014-12-23 |
2016-06-23 |
Olympus Winter & Ibe Gmbh |
HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
|
|
TWI525110B
(zh)
|
2014-12-24 |
2016-03-11 |
財團法人工業技術研究院 |
聚合物、及包含其之醫藥組合物
|
|
CN107406876B
(zh)
|
2014-12-31 |
2021-09-07 |
夸登特健康公司 |
表现出病变细胞异质性的疾病的检测和治疗以及用于传送测试结果的***和方法
|
|
JP2018501276A
(ja)
|
2015-01-09 |
2018-01-18 |
ギリアド アポロ， エルエルシー |
非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
|
|
WO2016115218A1
(en)
|
2015-01-14 |
2016-07-21 |
The California Institute For Biomedical Research |
Antibody drug conjugates for the treatment of immune conditions
|
|
WO2016115376A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
WO2016116935A1
(en)
|
2015-01-21 |
2016-07-28 |
Yeda Research And Development Co. Ltd. |
Use of rasa2 as a prognostic and therapeutic marker for melanoma
|
|
CN107531768A
(zh)
|
2015-01-23 |
2018-01-02 |
鹿特丹伊拉斯谟大学医疗中心 |
抗衰老化合物及其用途
|
|
CA2974958A1
(en)
|
2015-01-26 |
2016-08-04 |
Yale University |
Compositions and methods of using tyrosine kinase inhibitors
|
|
WO2016123054A2
(en)
|
2015-01-26 |
2016-08-04 |
The University Of North Carolina At Chapel Hill |
Kinase drug combinations and methods of use thereof
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US20180214449A1
(en)
|
2015-01-30 |
2018-08-02 |
Ubrx, Inc. |
Cancer therapy using jak inhibitor in combination with mapk inhibitors
|
|
WO2016126878A2
(en)
|
2015-02-03 |
2016-08-11 |
The Trustees Of The University Of Pennsylvania |
Listeria-based immunomodulation
|
|
CA2975673A1
(en)
|
2015-02-05 |
2016-08-11 |
Tyrnovo Ltd. |
Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
|
|
WO2016123679A1
(en)
|
2015-02-06 |
2016-08-11 |
Ferrao Petranel Theresa Christine |
A method of treatment
|
|
US20180021259A1
(en)
|
2015-02-10 |
2018-01-25 |
Memorial Sloan Kettering Cancer Center |
Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use
|
|
EP3258941A4
(en)
|
2015-02-17 |
2018-09-26 |
Cantex Pharmaceuticals, Inc. |
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
US10734117B2
(en)
|
2015-03-02 |
2020-08-04 |
Strand Life Sciences Private Limited |
Apparatuses and methods for determining a patient's response to multiple cancer drugs
|
|
MX371167B
(es)
|
2015-03-02 |
2020-01-21 |
Rigel Pharmaceuticals Inc |
Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
|
|
CA2978628A1
(en)
|
2015-03-03 |
2016-09-09 |
Caris Mpi, Inc. |
Molecular profiling for cancer
|
|
RS62915B1
(sr)
|
2015-03-03 |
2022-03-31 |
Biohaven Therapeutics Ltd |
Prolekovi riluzola i njihova primena
|
|
WO2016139331A1
(en)
|
2015-03-05 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of melanoma
|
|
KR20170129151A
(ko)
|
2015-03-19 |
2017-11-24 |
3-브이 바이오사이언시스, 인코포레이티드 |
지질 합성의 복소환식 조절제
|
|
RU2015110071A
(ru)
|
2015-03-23 |
2016-10-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" |
Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
|
|
PL3072529T3
(pl)
|
2015-03-26 |
2018-04-30 |
Ratiopharm Gmbh |
Kompozycja zawierająca wemurafenib i HPMC-AS
|
|
EP3072528B1
(en)
|
2015-03-26 |
2017-07-05 |
ratiopharm GmbH |
Composition comprising vemurafenib and cationic copolymer based on methacrylates
|
|
US20180078561A1
(en)
|
2015-03-31 |
2018-03-22 |
Lam Therapeutics, Inc. |
Active metabolites of apilimod and uses thereof
|
|
JP2016193848A
(ja)
|
2015-03-31 |
2016-11-17 |
東レ株式会社 |
Ｂｒａｆ阻害剤耐性メラノーマの治療又は予防剤
|
|
EP3277673B1
(en)
|
2015-04-01 |
2022-05-04 |
Rigel Pharmaceuticals, Inc. |
Tgf-beta inhibitors
|
|
EP3283479B1
(en)
|
2015-04-01 |
2022-12-14 |
Rigel Pharmaceuticals, Inc. |
Tgf-beta inhibitors
|
|
US10548989B2
(en)
|
2015-04-07 |
2020-02-04 |
Memorial Sloan Kettering Cancer Center |
Nanoparticle immunoconjugates
|
|
WO2016164641A1
(en)
|
2015-04-08 |
2016-10-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2016168150A2
(en)
|
2015-04-13 |
2016-10-20 |
The Board Of Regents Of The University Of Texas System |
Treatment for cancer metastasis
|
|
WO2016168264A1
(en)
|
2015-04-13 |
2016-10-20 |
Kiromic, Llc |
Methods and compositions for treating cancer with dendritic cells
|
|
CZ2015250A3
(cs)
|
2015-04-14 |
2016-10-26 |
Zentiva, K.S. |
Amorfní formy vemurafenibu
|
|
WO2016168612A1
(en)
|
2015-04-15 |
2016-10-20 |
Promedior, Inc. |
Methods for treating myeloproliferative disorders
|
|
EP3283111A4
(en)
|
2015-04-17 |
2019-04-17 |
Celldex Therapeutics, Inc. |
BIOMARKERS RELATED TO TREATMENT OF CANCER WITH HER3 AND EGFR INHIBITORS
|
|
WO2016168721A1
(en)
|
2015-04-17 |
2016-10-20 |
The Trustees Of The University Of Pennsylvania |
Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
|
|
US10702526B2
(en)
|
2015-04-20 |
2020-07-07 |
Effector Therapeutics Inc. |
Inhibitors of immune checkpoint modulators and related methods
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
UY36660A
(es)
|
2015-04-30 |
2016-11-30 |
Bayer Pharma AG |
Combinaciones de inhibidores de irak4
|
|
KR20160129609A
(ko)
|
2015-04-30 |
2016-11-09 |
삼성전자주식회사 |
Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
|
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
CA2984643A1
(en)
|
2015-05-13 |
2016-11-17 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
US10314854B2
(en)
|
2015-05-15 |
2019-06-11 |
University Of Iowa Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
US10604786B2
(en)
|
2015-05-20 |
2020-03-31 |
Pamgene Bv |
Method for predicting the response of melanoma patients to targeted pharmacotherapy
|
|
JP2018515570A
(ja)
|
2015-05-22 |
2018-06-14 |
プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． |
Ｂｒａｆ−ｖ６００関連疾患の治療に使用するためのｐｌｘ−８３９４またはｐｌｘ−７９０４
|
|
CA2986685A1
(en)
|
2015-05-27 |
2016-12-01 |
Quest Diagnostics Investments Incorporated |
Compositions and methods for screening solid tumors
|
|
WO2016196384A1
(en)
|
2015-05-29 |
2016-12-08 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
|
WO2016193955A1
(en)
|
2015-06-04 |
2016-12-08 |
Giorgio Stassi |
Combinations of kinase inhibitors for treating colorectal cancer
|
|
BR112017026140A2
(pt)
|
2015-06-05 |
2018-08-14 |
The Board Of Trustees Of The University Of Illinois |
método para inibir o crescimento ou a proliferação de células cancerígenas, método para induzir apoptose em célula cancerígena, método para tratar câncer, composição e seu uso
|
|
KR102643821B1
(ko)
|
2015-06-06 |
2024-03-07 |
클라우드브레이크 테라퓨틱스, 엘엘씨 |
익상편을 치료하기 위한 조성물 및 방법
|
|
WO2016200778A1
(en)
|
2015-06-08 |
2016-12-15 |
Children's Medical Center Corporation |
Methods for treatment of melanoma
|
|
WO2016200726A1
(en)
|
2015-06-08 |
2016-12-15 |
Texas Tech University System |
Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors
|
|
JP6890097B2
(ja)
|
2015-06-10 |
2021-06-18 |
エピザイム，インコーポレイティド |
リンパ腫を処置するためのｅｚｈ２阻害剤
|
|
WO2016201299A1
(en)
|
2015-06-12 |
2016-12-15 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
EP3103450A1
(en)
|
2015-06-12 |
2016-12-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
NZ737471A
(en)
|
2015-06-15 |
2022-02-25 |
Hangzhou Dac Biotech Co Ltd |
Hydrophilic linkers for conjugation
|
|
CN107921144B
(zh)
|
2015-06-20 |
2023-11-28 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
|
EP3314020A1
(en)
|
2015-06-29 |
2018-05-02 |
The Broad Institute Inc. |
Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
|
|
BR112017028218A2
(pt)
|
2015-06-30 |
2018-08-28 |
Genentech Inc |
?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos?
|
|
AR105483A1
(es)
|
2015-06-30 |
2017-10-11 |
Exelixis Inc |
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
|
|
CN113698335A
(zh)
|
2015-07-04 |
2021-11-26 |
杭州多禧生物科技有限公司 |
细胞结合分子的特异性偶联
|
|
WO2017005919A1
(en)
|
2015-07-08 |
2017-01-12 |
Biomedical Research Foundation Of The Academy Of Athens |
Novel compounds for use in treating or preventing cancerous diseases
|
|
US20180371550A1
(en)
|
2015-07-08 |
2018-12-27 |
Children's Hospital Medical Center |
Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
|
|
FI127517B
(sv)
|
2015-07-10 |
2018-08-15 |
Oy El Ho Ab |
Hydrauliska lösningar hos ett arbetsmaskin
|
|
CA2991805A1
(en)
|
2015-07-10 |
2017-01-19 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017019520A1
(en)
|
2015-07-24 |
2017-02-02 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods of cerenkov targeted and activated imaging and therapeutics
|
|
WO2017019804A2
(en)
|
2015-07-28 |
2017-02-02 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
EP3328372A4
(en)
|
2015-07-28 |
2019-03-20 |
University Of Iowa Research Foundation |
COMPOSITIONS AND METHODS OF TREATING CANCER
|
|
CA2991868A1
(en)
|
2015-07-31 |
2017-02-09 |
Vascular Biogenics Ltd. |
Motile sperm domain containing protein 2 and cancer
|
|
JP6903055B2
(ja)
|
2015-08-03 |
2021-07-14 |
イーエヌビー・セラピューティクス・インク |
Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法
|
|
US20180228740A1
(en)
|
2015-08-06 |
2018-08-16 |
The Wistar Institute Of Anatomy And Biology |
Combination therapies targeting mitochondrial biogenesis for cancer therapy
|
|
WO2017023994A1
(en)
|
2015-08-06 |
2017-02-09 |
Yale University |
Small molecule based antibody-recruiting compounds for cancer treatment
|
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
|
CN115300640A
(zh)
|
2015-08-10 |
2022-11-08 |
杭州多禧生物科技有限公司 |
新型连接体及其用于药物和生物分子的特异性偶联
|
|
CN112494659B
(zh)
|
2015-08-18 |
2023-08-08 |
乐天医药生技股份有限公司 |
酞菁染料偶联物的制造方法及稳定偶联物
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
CN108290944B
(zh)
|
2015-08-18 |
2022-05-17 |
梅约医学教育与研究基金会 |
载体结合剂组合物及其制备和使用方法
|
|
WO2017031427A1
(en)
|
2015-08-19 |
2017-02-23 |
3-V Biosciences, Inc. |
COMPOUNDS AND METHODS FOR INHIBITING mTOR
|
|
US20170056327A1
(en)
|
2015-08-25 |
2017-03-02 |
The Methodist Hospital |
Micro/nano composite drug delivery formulations and uses thereof
|
|
WO2017037579A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
WO2017040990A1
(en)
|
2015-09-03 |
2017-03-09 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
MY195977A
(en)
|
2015-09-21 |
2023-02-27 |
Plexxikon Inc |
Heterocyclic Compounds and uses Thereof
|
|
US10016422B2
(en)
|
2015-09-30 |
2018-07-10 |
Oregon State University |
Nanocarrier drug delivery platform
|
|
US20180271808A1
(en)
|
2015-10-01 |
2018-09-27 |
Mitchell Woods Pharmaceuticals, Inc. |
Methods of reducing chemoresistance and treating cancer
|
|
US10864179B2
(en)
|
2015-10-01 |
2020-12-15 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
|
|
US20180280393A1
(en)
|
2015-10-06 |
2018-10-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treatment of metastatic and refractory cancers and tumors
|
|
WO2017066193A1
(en)
|
2015-10-15 |
2017-04-20 |
Princeton Drug Discovery, Llc |
Novel inhibitors of protein kinases
|
|
WO2017067592A1
(en)
|
2015-10-21 |
2017-04-27 |
Biontech Ag |
Cytotoxic immunostimulating particles and uses thereof
|
|
US10646576B2
(en)
|
2015-10-21 |
2020-05-12 |
Sprna Gmbh |
Immunostimulating-toxic RNA in alkaline earth metal formulation
|
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
|
MX2018005340A
(es)
|
2015-11-02 |
2018-05-17 |
Univ Yale |
Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
|
|
EP3371221A2
(en)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
US9695150B2
(en)
|
2015-11-14 |
2017-07-04 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
WO2017083788A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
AU2016355320B2
(en)
|
2015-11-19 |
2023-12-07 |
Genentech, Inc. |
Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors
|
|
CN108431601B
(zh)
|
2015-11-20 |
2021-04-27 |
特里特福尔莱弗公司 |
组织样本中药物结合分析的方法
|
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
|
US20180369195A1
(en)
|
2015-11-30 |
2018-12-27 |
The Regents Of The University Of California |
Combination therapy for treatment of melanoma
|
|
CN108603232A
(zh)
|
2015-12-03 |
2018-09-28 |
阿尔佛雷德医疗集团 |
监测骨髓瘤的治疗或进展
|
|
WO2017099591A1
(en)
|
2015-12-07 |
2017-06-15 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Treatment of inhibitor resistant braf-mutant cancers
|
|
WO2017100201A1
(en)
|
2015-12-07 |
2017-06-15 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2017098336A1
(en)
|
2015-12-11 |
2017-06-15 |
Laurus Labs Private Limited |
Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof
|
|
WO2017106189A1
(en)
|
2015-12-14 |
2017-06-22 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ras/mapk mutant lung cancer
|
|
KR20180086502A
(ko)
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
|
WO2017117182A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
|
WO2017117052A1
(en)
|
2015-12-31 |
2017-07-06 |
Effector Therapeutics, Inc. |
Mnk biomarkers and uses thereof
|
|
WO2017120600A1
(en)
|
2016-01-08 |
2017-07-13 |
Clearside Biomedical, Inc. |
Compositions and methods of treating wet age-related macular degeneration
|
|
WO2017127282A1
(en)
|
2016-01-19 |
2017-07-27 |
The General Hospital Corporation |
Cancer treatments and methods of selecting same
|
|
ES2905208T3
(es)
|
2016-01-27 |
2022-04-07 |
Fraunhofer Ges Forschung |
Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa
|
|
EP3407978A4
(en)
|
2016-01-29 |
2020-01-15 |
Epizyme Inc |
COMBINATION THERAPY FOR TREATING CANCER
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
CN107709288A
(zh)
|
2016-02-03 |
2018-02-16 |
四川海思科制药有限公司 |
一种磷酰胺衍生物及制备方法和用途
|
|
WO2016059622A2
(en)
|
2016-02-04 |
2016-04-21 |
Suzhou M-Conj Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
|
CN117159571A
(zh)
|
2016-02-04 |
2023-12-05 |
Sct二代有限责任公司 |
用于抵抗蒽环类诱导的心脏毒性的药物组合物和用途
|
|
AU2017214574A1
(en)
|
2016-02-05 |
2018-09-27 |
Evol Science LLC |
Combinations to treat cancer
|
|
US20170226518A1
(en)
|
2016-02-09 |
2017-08-10 |
Autotelic Llc |
Compositions and methods for treating cancer
|
|
WO2017138925A1
(en)
|
2016-02-09 |
2017-08-17 |
Autotelic Llc |
Antitumour combinations of antisense oligonucleotides and anticancer agents
|
|
EP3419668A4
(en)
|
2016-02-24 |
2019-10-09 |
Ramot at Tel-Aviv University Ltd. |
POLYMER CONJUGATES AND USES THEREOF
|
|
WO2017145179A1
(en)
|
2016-02-24 |
2017-08-31 |
Indian Institute Of Technology, Bombay |
Drug delivery system
|
|
JP2019509282A
(ja)
|
2016-02-29 |
2019-04-04 |
ファウンデーション・メディシン・インコーポレイテッド |
癌の治療方法
|
|
WO2017151762A1
(en)
|
2016-03-01 |
2017-09-08 |
Intezyne Technologies |
Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer
|
|
CN108884098B
(zh)
|
2016-03-08 |
2021-09-14 |
拜耳制药股份公司 |
2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
|
|
ES2947237T3
(es)
|
2016-03-10 |
2023-08-03 |
Lutris Pharma Ltd |
Uso de inhibidores de BRaf para el tratamiento de reacciones cutáneas
|
|
CA3017972C
(en)
|
2016-03-16 |
2023-03-28 |
Plexxikon Inc. |
Compounds and methods for kinase modulation and indications therefore
|
|
WO2017161188A1
(en)
|
2016-03-16 |
2017-09-21 |
The Regents Of The University Of California |
Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
|
|
KR101921676B1
(ko)
|
2016-03-22 |
2018-11-26 |
한국과학기술원 |
Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법
|
|
WO2017162510A1
(en)
|
2016-03-24 |
2017-09-28 |
Bayer Pharma Aktiengesellschaft |
Substituted quinazolinone compounds for the treatment of proliferative diseases
|
|
WO2017176565A1
(en)
|
2016-04-07 |
2017-10-12 |
Eli Lilly And Company |
Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
|
|
EP3442996A4
(en)
|
2016-04-12 |
2019-11-27 |
Blaze Bioscience, Inc. |
METHODS OF TREATMENT INVOLVING CHLOROTOXIN CONJUGATES
|
|
KR102548385B1
(ko)
|
2016-04-14 |
2023-06-28 |
크리에티브이 마이크로테크, 인크. |
암 요법을 위한 치료 결정에서 pd-l1 발현을 사용하는 방법
|
|
WO2017181149A1
(en)
|
2016-04-15 |
2017-10-19 |
Blaze Bioscience, Inc. |
Methods of treating breast cancer
|
|
US10543285B2
(en)
|
2016-04-15 |
2020-01-28 |
The Penn State Researh Foundation |
Compositions and methods for targeted delivery of therapeutic and/or diagnostic agents
|
|
CN109072311A
(zh)
|
2016-04-15 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
WO2017184534A1
(en)
|
2016-04-18 |
2017-10-26 |
The Gorlin Companies |
Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
|
|
US20170312273A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
|
US20200397894A1
(en)
|
2016-04-27 |
2020-12-24 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
|
JP2019112307A
(ja)
|
2016-04-28 |
2019-07-11 |
宇部興産株式会社 |
置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物
|
|
WO2017193086A1
(en)
|
2016-05-06 |
2017-11-09 |
Tarrex Biopharma Inc. |
Therapeutic compounds and methods
|
|
US10898547B2
(en)
|
2016-05-10 |
2021-01-26 |
Unicorn Therapeutics, Llc |
Method of treatment of breast or colon cancer by administering muscle stimulated myokines
|
|
JP6751157B2
(ja)
|
2016-05-12 |
2020-09-02 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
疾患を治療するために標的へ向けられた薬物の効力を予測するためのシステム
|
|
WO2017200826A1
(en)
|
2016-05-16 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Assays and compounds for treatment of cancer
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
JP6103111B1
(ja)
|
2016-05-24 |
2017-03-29 |
三生医薬株式会社 |
経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
|
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
|
IL298701B2
(en)
|
2016-05-25 |
2024-03-01 |
Caris Science Inc |
Oligonucleotide probes and their uses
|
|
EP3463370A4
(en)
|
2016-05-27 |
2020-04-08 |
The Board of Regents of The University of Texas System |
6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) CAUSES TELOMERASE DEPENDENT TELEOMERS AND CELL DEATH IN THERAPY RESISTANT CANCER CELLS
|
|
WO2017210580A1
(en)
|
2016-06-03 |
2017-12-07 |
Enlibrium, Inc. |
Imidodicarbonimidic diamide analogs
|
|
WO2017212420A1
(en)
|
2016-06-07 |
2017-12-14 |
Centre For Cellular And Molecular Platforms |
Methods and compositions for managing neuroinflammation and neurodegeneration
|
|
WO2017218365A1
(en)
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
GB201610628D0
(en)
|
2016-06-17 |
2016-08-03 |
Mihranyan Albert |
New compositions
|
|
US11369618B2
(en)
|
2016-06-17 |
2022-06-28 |
The Trustees Of The University Of Pennsylvania |
Compounds, compositions and methods for prevention and/or treatment of cancer
|
|
WO2017222958A1
(en)
|
2016-06-20 |
2017-12-28 |
Kura Oncology, Inc. |
Treatment of squamous cell carcinomas with inhibitors of erk
|
|
US20190262343A1
(en)
|
2016-06-21 |
2019-08-29 |
The Regents Of The University Of California |
Wound healing using braf inhibitors
|
|
AU2017281940A1
(en)
|
2016-06-24 |
2019-01-24 |
University Of Iowa Research Foundation |
Compositions and methods of treating melanoma
|
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
CA3027911A1
(en)
|
2016-06-30 |
2018-01-04 |
Nant Holdings Ip, Llc |
Coordinated treatment regimen to treat a tumor
|
|
PL3478684T3
(pl)
|
2016-07-01 |
2020-08-10 |
Fermion Oy |
Nowe sposoby otrzymywania wemurafenibu
|
|
US20180010114A1
(en)
|
2016-07-05 |
2018-01-11 |
Polaris Group |
Combination cancer immunotherapies with arginine depletion agents
|
|
EP3481410A2
(en)
|
2016-07-08 |
2019-05-15 |
Paul C. Tumeh |
Compositions and treatment methods for cancer immunotherapy
|
|
MA45625A
(fr)
|
2016-07-08 |
2019-05-15 |
Genmab As |
Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
|
|
US10711312B2
(en)
|
2016-07-12 |
2020-07-14 |
The Regents Of The University Of California |
Methods for immunotherapy-based treatment and assessment of cancer
|
|
EP3269365A1
(en)
|
2016-07-14 |
2018-01-17 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Kras inhibitor for use in treating cancer
|
|
US20180015075A1
(en)
|
2016-07-14 |
2018-01-18 |
Children's Hospital Medical Center |
Methods and compositions for treatment of venous malformation
|
|
CA2937896A1
(en)
|
2016-08-02 |
2018-02-02 |
Universite De Montreal |
Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia
|
|
WO2018031707A1
(en)
|
2016-08-10 |
2018-02-15 |
Biohaven Pharmaceutical Holding Company Ltd. |
Acyl benzo[d]thiazol-2-amine and their methods of use
|
|
CN109563128B
(zh)
|
2016-08-16 |
2023-02-28 |
国立研究开发法人产业技术总合研究所 |
恶性肿瘤靶向肽
|
|
EP3500686B1
(en)
|
2016-08-18 |
2024-01-10 |
Quest Diagnostics Investments LLC |
Methods for detecting craniopharyngioma and for selecting medicaments and patients for treatment
|
|
WO2018045058A1
(en)
|
2016-08-30 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
|
EP3506942B1
(en)
|
2016-09-01 |
2022-11-16 |
Mayo Foundation for Medical Education and Research |
Carrier-pd-l1 binding agent compositions for treating cancers
|
|
KR20190053203A
(ko)
|
2016-09-01 |
2019-05-17 |
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 |
Ｔ－세포 암을 표적화하는 방법 및 조성물
|
|
WO2018049015A1
(en)
|
2016-09-07 |
2018-03-15 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and pd-1 antagonists
|
|
EP3510175A4
(en)
|
2016-09-08 |
2020-06-24 |
Curematch, Inc. |
OPTIMIZATION OF THERAPEUTIC OPTIONS IN PERSONALIZED MEDICINE
|
|
CN109715163B
(zh)
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
|
|
EP3519436A4
(en)
|
2016-09-30 |
2020-09-09 |
Baylor College of Medicine |
TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
|
|
WO2018071549A1
(en)
|
2016-10-11 |
2018-04-19 |
New York University |
Nanoparticles and uses thereof
|
|
IL248468A0
(en)
|
2016-10-13 |
2017-01-31 |
Technion Res & Dev Foundation |
Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing
|
|
WO2018075801A1
(en)
|
2016-10-19 |
2018-04-26 |
Signpath Pharma, Inc. |
Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
|
|
WO2018075447A1
(en)
|
2016-10-19 |
2018-04-26 |
The Trustees Of Columbia University In The City Of New York |
Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
|
|
CA3042697A1
(en)
|
2016-11-03 |
2018-05-11 |
The Regents Of The University Of Michigan |
Small molecule dual inhibitors of egfr/pi3k and uses thereof
|
|
MX2019005141A
(es)
|
2016-11-09 |
2019-09-26 |
Signpath Pharma Inc |
Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
|
|
WO2018086139A1
(en)
|
2016-11-14 |
2018-05-17 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
|
WO2018093724A1
(en)
|
2016-11-15 |
2018-05-24 |
Quest Diagnostics Investments Llc |
Methods for detecting dna mutations using mitra tip extraction
|
|
EP3541400A2
(en)
|
2016-11-18 |
2019-09-25 |
Sanford Burnham Prebys Medical Discovery Institute |
Gut microbiota and treatment of cancer
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CA3043131A1
(en)
|
2016-11-18 |
2018-05-24 |
Neurovive Pharmaceutical Ab |
Use of sanglifehrin macrocyclic analogues as anticancer compounds
|
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
CN108148071B
(zh)
|
2016-11-25 |
2019-10-15 |
广东东阳光药业有限公司 |
氨基喹唑啉衍生物的盐及其用途
|
|
AU2017366721A1
(en)
|
2016-12-01 |
2019-05-02 |
Ellipses Pharma Limited |
Treatment of cancer
|
|
US11473088B2
(en)
|
2016-12-02 |
2022-10-18 |
Ohio University |
Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
US20190285615A1
(en)
|
2016-12-19 |
2019-09-19 |
Nantbio, Inc. |
Methods and artificial tumors for validating an antitumor immune response
|
|
JP7190432B2
(ja)
|
2016-12-20 |
2022-12-15 |
イーティーエイチ・チューリッヒ |
がんにおける非遺伝的薬物耐性プログラムを標的とする薬物の同定
|
|
EP3559674B1
(en)
|
2016-12-20 |
2021-07-07 |
Treat4Life AB |
A method to determine braf mutations and wild type braf protein by mass spectrometry
|
|
WO2018115888A1
(en)
|
2016-12-21 |
2018-06-28 |
N4 Pharma Uk Limited |
Novel formulations of aprepitant
|
|
KR102564201B1
(ko)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
TW201825087A
(zh)
|
2017-01-05 |
2018-07-16 |
杏國新藥股份有限公司 |
胰臟癌治療
|
|
FR3061658A1
(fr)
|
2017-01-07 |
2018-07-13 |
Guy Faustin Monkam Nitcheu |
Composition pharmaceutique comprenant en tant que principe actif une combinaison de d-limoneme, de lupeol et du cinnamaldehyde et/ou du methylhydroxychalcone polymere et/ou du beta-sitosterol et/ou de
|
|
WO2018132660A1
(en)
|
2017-01-13 |
2018-07-19 |
University Of Miami |
Integrator inhibitors and methods for their use
|
|
JP7300394B2
(ja)
|
2017-01-17 |
2023-06-29 |
ヘパリジェニックス ゲーエムベーハー |
肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
|
|
TR201702500A2
(tr)
|
2017-02-20 |
2017-07-21 |
Anadolu Ueniversitesi |
Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
|
|
US9861833B1
(en)
|
2017-03-30 |
2018-01-09 |
Norman H. Anderson |
Methods of treating melanoma
|